keyword
MENU ▼
Read by QxMD icon Read
search

edss

keyword
https://www.readbyqxmd.com/read/28239937/smoking-does-not-influence-disability-accumulation-in-primary-progressive-multiple-sclerosis
#1
O Javizian, L M Metz, S Deighton, M W Koch
BACKGROUND AND PURPOSE: The modifiable risk factor cigarette smoking has been associated with an increased risk of developing multiple sclerosis (MS) and with disease activity in relapsing-remitting MS. However, less is known about the effect of smoking on disease progression in progressive MS. Here the association between cigarette smoking and disability accumulation in primary progressive MS (PPMS) is investigated. METHODS: Kaplan-Meier survival analyses and Cox proportional hazard modelling were used to investigate the influence of cigarette smoking on the risk of reaching Expanded Disability Status Scale (EDSS) 4 and 6 as well as the time from EDSS 4 to 6 in patients with PPMS...
February 26, 2017: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/28239524/pattern-of-gray-matter-volumes-related-to-retinal-thickness-and-its-association-with-cognitive-function-in-relapsing-remitting-ms
#2
Jan-Patrick Stellmann, Hanife Cetin, Kim Lea Young, Sibylle Hodecker, Jana Pöttgen, Diana Bittersohl, Andrea Hassenstein, Timm Oberwahrenbrock, Christoph Heesen, Susanne Siemonsen
BACKGROUND: Neurodegeneration in multiple sclerosis (MS) may be investigated in the visual system as optical coherence tomography (OCT) and magnetic resonance imaging (MRI) allows examining structural integrity in detail. The association between thickness of retinal layers and focal cortical volumes beyond the primary visual system has not been thoroughly investigated. OBJECTIVE: To investigate the association between focal cortical volume and thickness of retinal layers...
February 2017: Brain and Behavior
https://www.readbyqxmd.com/read/28235811/fast-multiple-sclerosis-progression-in-north-africans-both-genetics-and-environment-matter
#3
Youssef Sidhom, Elisabeth Maillart, Sophie Tezenas du Montcel, Imen Kacem, Catherine Lubetzki, Riadh Gouider, Caroline Papeix
OBJECTIVE: To compare multiple sclerosis (MS) disability progression among North Africans (NAs) living in France (NAF) and in Tunisia (NAT) and Caucasian patients born and living in France (CF). METHODS: Patients with MS admitted to the day hospital in the Neurology Department at Pitié-Salpêtrière Hospital (France) and Razi Hospital (Tunisia) were questioned on their place of birth and the place of birth of their parents. To compare delay to outcomes, log-rank tests were used...
February 24, 2017: Neurology
https://www.readbyqxmd.com/read/28231687/the-assessment-of-disease-characteristics-on-multiple-sclerosis-patients-quality-of-life-in-iran
#4
Aziz Rezapoor, Abdollah Almasian Kia, Sahar Goodarzi, Mojtaba Hasoumi, Soraya Nouraei Motlagh, Sajad Vahedi
Objectives: The aim of this study was to assess the quality of life in patients with multiple sclerosis, and predict the effect of MS characteristics such as disease course, disease severity and relapse on patients' quality of life. Methods: In a cross-sectional study, 171 patients enrolled in the study. The health related quality of life were assessed through Persian version of MSQoL54 questionnaire. To measure patients' disability status, we used Expanded Disability Status Scale (EDSS)...
February 19, 2017: Epidemiology and Health
https://www.readbyqxmd.com/read/28231474/early-disturbances-in-multimodal-evoked-potentials-as-a-prognostic-factor-for-long-term-disability-in-relapsing-remitting-multiple-sclerosis-patients
#5
Frédéric London, Souraya El Sankari, Vincent van Pesch
OBJECTIVE: The aim of this study was to investigate whether early alterations in evoked potentials (EPs) have a prognostic value in relapsing-remitting multiple sclerosis (RRMS). METHODS: We retrospectively selected 108 early MS patients with a neurological follow-up ranging from 5 to 15years, in whom multimodal EPs (visual, brainstem auditory, somatosensory and motor) were performed at diagnosis. A conventional ordinal score was used to quantify the observed abnormalities...
January 28, 2017: Clinical Neurophysiology: Official Journal of the International Federation of Clinical Neurophysiology
https://www.readbyqxmd.com/read/28222549/gait-and-balance-deterioration-over-a-12-month-period-in-multiple-sclerosis-patients-with-edss-scores-%C3%A2-3-0
#6
Mary P Galea, L Eduardo Cofré Lizama, Helmut Butzkueven, Trevor J Kilpatrick
BACKGROUND AND PURPOSE: It is not currently known whether gait and balance measures are responsive to deterioration of motor function in multiple sclerosis (MS) patients with low EDSS scores (≤3.0). The aim of this study was to quantify MS-related gait and balance deterioration over a 12-month period. METHODS: Thirty-eight participants with MS (33 female, mean age: 41.1 ± 8.3 years), mean time since diagnosis 2.2 ± 4.1 years, EDSS score ≤3.0 and without clinical evidence of gait deterioration, were recruited...
February 6, 2017: NeuroRehabilitation
https://www.readbyqxmd.com/read/28211827/association-between-gait-variability-falls-and-mobility-in-people-with-multiple-sclerosis-a-specific-observation-on-the-edss-4-0-4-5-level
#7
Alon Kalron
BACKGROUND: We previously demonstrated that gait variability increases throughout the disease process in people with multiple sclerosis (PwMS). While gait variability tends to remain steady in the lower levels of disability, a significant increase occurs once patients reach the moderate neurological level. OBJECTIVE: To examine the relationship between variability of major spatio-temporal parameters of gait and falls, in PwMS with an expanded disability status scale score of 4...
February 13, 2017: NeuroRehabilitation
https://www.readbyqxmd.com/read/28209373/cost-utility-of-first-line-disease-modifying-treatments-for-relapsing-remitting-multiple-sclerosis
#8
Erkki Soini, Jaana Joutseno, Marja-Liisa Sumelahti
PURPOSE: This study evaluated the cost-effectiveness of first-line treatments of relapsing-remitting multiple sclerosis (RRMS) (dimethyl fumarate [DMF] 240 mg PO BID, teriflunomide 14 mg once daily, glatiramer acetate 20 mg SC once daily, interferon [IFN]-β1a 44 µg TIW, IFN-β1b 250 µg EOD, and IFN-β1a 30 µg IM QW) and best supportive care (BSC) in the health care payer setting in Finland. METHODS: The primary outcome was the modeled incremental cost-effectiveness ratio (ICER; €/quality-adjusted life-year [QALY] gained, 3%/y discounting)...
February 13, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28209331/treatment-effectiveness-of-alemtuzumab-compared-with-natalizumab-fingolimod-and-interferon-beta-in-relapsing-remitting-multiple-sclerosis-a-cohort-study
#9
Tomas Kalincik, J William L Brown, Neil Robertson, Mark Willis, Neil Scolding, Claire M Rice, Alastair Wilkins, Owen Pearson, Tjalf Ziemssen, Michael Hutchinson, Christopher McGuigan, Vilija Jokubaitis, Tim Spelman, Dana Horakova, Eva Havrdova, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Raed Alroughani, Eugenio Pucci, Patrizia Sola, Raymond Hupperts, Jeannette Lechner-Scott, Murat Terzi, Vincent Van Pesch, Csilla Rozsa, François Grand'Maison, Cavit Boz, Franco Granella, Mark Slee, Daniele Spitaleri, Javier Olascoaga, Roberto Bergamaschi, Freek Verheul, Steve Vucic, Pamela McCombe, Suzanne Hodgkinson, Jose Luis Sanchez-Menoyo, Radek Ampapa, Magdolna Simo, Tunde Csepany, Cristina Ramo, Edgardo Cristiano, Michael Barnett, Helmut Butzkueven, Alasdair Coles
BACKGROUND: Alemtuzumab, an anti-CD52 antibody, is proven to be more efficacious than interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy relative to more potent immunotherapies is unknown. We compared the effectiveness of alemtuzumab with natalizumab, fingolimod, and interferon beta in patients with relapsing-remitting multiple sclerosis treated for up to 5 years. METHODS: In this international cohort study, we used data from propensity-matched patients with relapsing-remitting multiple sclerosis from the MSBase and six other cohorts...
February 10, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28206829/validity-of-low-contrast-letter-acuity-as-a-visual-performance-outcome-measure-for-multiple-sclerosis
#10
Laura J Balcer, Jenelle Raynowska, Rachel Nolan, Steven L Galetta, Raju Kapoor, Ralph Benedict, Glenn Phillips, Nicholas LaRocca, Lynn Hudson, Richard Rudick
Low-contrast letter acuity (LCLA) has emerged as the leading outcome measure to assess visual disability in multiple sclerosis (MS) research. As visual dysfunction is one of the most common manifestations of MS, sensitive visual outcome measures are important in examining the effect of treatment. Low-contrast acuity captures visual loss not seen in high-contrast visual acuity (HCVA) measurements. These issues are addressed by the MS Outcome Assessments Consortium (MSOAC), including representatives from advocacy organizations, Food and Drug Administration (FDA), European Medicines Agency (EMA), National Institute of Neurological Disorders and Stroke (NINDS), academic institutions, and industry partners along with persons living with MS...
February 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28203460/the-prevalence-of-anti-aquaporin-4-antibody-in-patients-with-idiopathic-inflammatory-demyelinating-diseases-presented-to-a-tertiary-hospital-in-malaysia-presentation-and-prognosis
#11
S Abdullah, W F Wong, C T Tan
Background. There have been inconsistent reports on the prevalence and pathogenicity of anti-Aquaporin 4 (AQP4) in patients presented with idiopathic inflammatory demyelinating diseases (IIDDs). Objective. To estimate the prevalence of anti-AQP4 antibody in patients with IIDDs presented to University Malaya Medical Centre in terms of patients' clinical and radiological presentations and prognoses. Methods. Retrospective data review of IIDDs patients presented from 2005 to 2015. Patients were classified into classical multiple sclerosis (CMS), opticospinal (OS) presentation, optic neuritis (ON), transverse myelitis (TM), brainstem syndrome (BS), and tumefactive MS...
2017: Multiple Sclerosis International
https://www.readbyqxmd.com/read/28196747/socs-gene-family-expression-profile-in-the-blood-of-multiple-sclerosis-patients
#12
Mehdi Toghi, Mohammad Taheri, Shahram Arsang-Jang, Mina Ohadi, Reza Mirfakhraie, Mehrdokht Mazdeh, Arezou Sayad
Multiple sclerosis (MS) is a chronic autoimmune disease, and the most common cause of nontraumatic disability in young people. The etiology of this disease is not well defined yet. Cytokines play an important role in differentiation, maturation and survival of a wide range of cells, including cells of the immune system. Suppressor of cytokine signaling (SOCS) proteins are the most important regulators of this cytokine signaling pathway. The aim of present study was to compare the expression levels of SOCS1, SOCS2, SOCS3 and SOCS5 genes in the blood of 50 relapsing-remitting MS (RR-MS) patients and 50 healthy controls by Taqman Quantitative Real-Time PCR in patients and healthy control group...
February 9, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/28192539/optical-coherence-tomography-segmentation-analysis-in-relapsing-remitting-versus-progressive-multiple-sclerosis
#13
Raed Behbehani, Abdullah Abu Al-Hassan, Ali Al-Salahat, Devarajan Sriraman, J D Oakley, Raed Alroughani
INTRODUCTION: Optical coherence tomography (OCT) with retinal segmentation analysis is a valuable tool in assessing axonal loss and neuro-degeneration in multiple sclerosis (MS) by in-vivo imaging, delineation and quantification of retinal layers. There is evidence of deep retinal involvement in MS beyond the inner retinal layers. The ultra-structural retinal changes in MS in different MS phenotypes can reflect differences in the pathophysiologic mechanisms. There is limited data on the pattern of deeper retinal layer involvement in progressive MS (PMS) versus relapsing remitting MS (RRMS)...
2017: PloS One
https://www.readbyqxmd.com/read/28187977/retinal-and-optic-nerve-degeneration-in-patients-with-multiple-sclerosis-followed-up-for-5-years
#14
Elena Garcia-Martin, Jose R Ara, Jesus Martin, Carmen Almarcegui, Isabel Dolz, Elisa Vilades, Laura Gil-Arribas, Francisco J Fernandez, Vicente Polo, Jose M Larrosa, Luis E Pablo, Maria Satue
PURPOSE: To quantify retinal nerve fiber layer (RNFL) changes in patients with multiple sclerosis (MS) and healthy controls with a 5-year follow-up and to analyze correlations between disability progression and RNFL degeneration. DESIGN: Observational and longitudinal study. PARTICIPANTS: One hundred patients with relapsing-remitting MS and 50 healthy controls. METHODS: All participants underwent a complete ophthalmic and electrophysiologic exploration and were re-evaluated annually for 5 years...
February 7, 2017: Ophthalmology
https://www.readbyqxmd.com/read/28180139/metabolomic-signatures-associated-with-disease-severity-in-multiple-sclerosis
#15
Pablo Villoslada, Cristina Alonso, Ion Agirrezabal, Ekaterina Kotelnikova, Irati Zubizarreta, Irene Pulido-Valdeolivas, Albert Saiz, Manuel Comabella, Xavier Montalban, Luisa Villar, Jose Carlos Alvarez-Cermeño, Oscar Fernández, Roberto Alvarez-Lafuente, Rafael Arroyo, Azucena Castro
OBJECTIVE: To identify differences in the metabolomic profile in the serum of patients with multiple sclerosis (MS) compared to controls and to identify biomarkers of disease severity. METHODS: We studied 2 cohorts of patients with MS: a retrospective longitudinal cohort of 238 patients and 74 controls and a prospective cohort of 61 patients and 41 controls with serial serum samples. Patients were stratified into active or stable disease based on 2 years of prospective assessment accounting for presence of clinical relapses or changes in disability measured with the Expanded Disability Status Scale (EDSS)...
March 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28173728/metabolic-changes-in-normal-appearing-white-matter-in-patients-with-neuromyelitis-optica-and-multiple-sclerosis-a-comparative-magnetic-resonance-spectroscopy-study
#16
Yunyun Duan, Zheng Liu, Yaou Liu, Jing Huang, Zhuoqiong Ren, Zheng Sun, Hai Chen, Huiqing Dong, Jing Ye, Kuncheng Li
Background Previous studies with a small sample size have not reported metabolic changes in neuromyelitis optica (NMO). Metabolic changes, such as decreased N-acetylaspartate (NAA), are well-established in patients with multiple sclerosis (MS). It remains unknown whether different patterns of metabolic changes occur in NMO and MS. Purpose To investigate the metabolic changes in normal-appearing white matter (NAWM) in NMO, compared with MS patients and healthy controls (HC), and correlate these changes with clinical disability...
January 1, 2017: Acta Radiologica
https://www.readbyqxmd.com/read/28155580/age-related-multiple-sclerosis-severity-score-disability-ranked-by-age
#17
Ali Manouchehrinia, Helga Westerlind, Elaine Kingwell, Feng Zhu, Robert Carruthers, Ryan Ramanujam, Maria Ban, Anna Glaser, Stephen Sawcer, Helen Tremlett, Jan Hillert
BACKGROUND: The Multiple Sclerosis Severity Score (MSSS) is obtained by normalising the Expanded Disability Status Scale (EDSS) score for disease duration and has been a valuable tool in cross-sectional studies. OBJECTIVE: To assess whether use of age rather than the inherently ambiguous disease duration was a feasible approach. METHOD: We pooled disability data from three population-based cohorts and developed an Age Related Multiple Sclerosis Severity (ARMSS) score by ranking EDSS scores based on the patient's age at the time of assessment...
January 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28155573/oral-contraceptives-and-ms-disease-activity-in-a-contemporary-real-world-cohort
#18
Riley Bove, Kelsey Rankin, Alicia S Chua, Taylor Saraceno, Neda Sattarnezhad, Emily Greeke, Fiona Stuart, Allison LaRussa, Bonnie I Glanz, Tanuja Chitnis
BACKGROUND: There is uncertainty regarding the effect of oral hormonal contraceptives (OC) on multiple sclerosis (MS) course. OBJECTIVE: To evaluate the hypothesis that OC use is associated with decreased risk of relapses in an observational study of women of childbearing age with new-onset MS starting a first-line injectable disease-modifying therapy (DMT). METHODS: From our CLIMB longitudinal observational study, we identified 162 women with MS or CIS with known OC use who initiated injectable DMT within two years of symptom onset, and categorized OC use at DMT onset as past, ever or never...
February 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28152396/insulin-resistance-atherogenicity-and-iron-metabolism-in-multiple-sclerosis-with-and-without-depression-associations-with-inflammatory-and-oxidative-stress-biomarkers-and-uric-acid
#19
Sayonara Rangel Oliveira, Ana Paula Kallaur, Josiane Lopes, Andrea Name Colado Simão, Edna Maria Vissoci Reiche, Elaine Regina Delicato de Almeida, Helena Kaminami Morimoto, Wildea Lice de Carvalho Jennings de Pereira, Daniela Frizon Alfieri, Tamires Flauzino, Caio de Meleck Proença, Anna Maria Gomes, Damacio Ramón Kaimen-Maciel, Michael Maes
Depression is accompanied by metabolic disorders in iron metabolism, lipoproteins, and insulin resistance. We measured plasma levels of ferritin, iron, lipids, insulin, and glucose and computed the homeostasis model assessment (HOMA2IR) and atherogenic index of plasma (AIP) in MS patients with and without depression and healthy controls. Explanatory variables were serum uric acid, interleukin (IL)-6, lipid hydroperoxides (CL-LOOH), albumin, and C-reactive protein (CRP). Depression was assessed using the Hospital Anxiety and Depression Scale (HADS), neurological disability using the Expanded Disability Status Scale (EDSS), and disease progression using ∆EDSS over five years earlier...
December 27, 2016: Psychiatry Research
https://www.readbyqxmd.com/read/28151074/a-systematic-review-of-the-effects-of-modifiable-risk-factor-interventions-on-the-progression-of-multiple-sclerosis
#20
Susanne Hempel, Glenn D Graham, Ning Fu, Elena Estrada, Annie Y Chen, Isomi Miake-Lye, Jeremy N V Miles, Roberta Shanman, Paul G Shekelle, Jessica M Beroes, Mitchell T Wallin
BACKGROUND: Several risk factors are associated with multiple sclerosis (MS) progression and may be amenable to intervention. OBJECTIVE: To systematically review the evidence for interventions targeting risk factors for MS progression. METHODS: We searched six databases and existing reviews till March 2015 and consulted with experts to identify randomized controlled trials (RCTs) of interventions targeting MS risk factors (PROSPERO 2015:CRD42015016461)...
February 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
keyword
keyword
84088
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"